As of 2026-04-05, the EV/EBITDA ratio of Cymabay Therapeutics Inc (CBAY) is -36.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CBAY's latest enterprise value is 3,631.48 mil USD. CBAY's TTM EBITDA according to its financial statements is -99.22 mil USD. Dividing these 2 quantities gives us the above CBAY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 8.9x | 8.1x |
| Forward P/E multiples | 10.6x - 14.1x | 12.6x |
| Fair Price | (8.28) - (6.87) | (8.12) |
| Upside | -125.5% - -121.1% | -125.0% |
| Date | EV/EBITDA |